By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on Biotechnology are discussed in a new report. According to news originating from Barcelona, Spain, by NewsRx correspondents, research stated, "Mycobacterium bovis bacillus Calmette-Guerin is the most effective treatment for high risk noninvasive bladder cancer. Although bacillus Calmette-Guerin immunotherapy clearly decreases recurrence and progression rates, side effects are common and infection with the bacillus has been described."
Our news journalists obtained a quote from the research from Autonomous University, "For these reasons it is necessary to find safer alternatives to the live bacillus. We explored the possibility of using killed but metabolically active bacillus Calmette-Guerin. T24, J82 and RT4 bladder tumor cell lines were cultured with live and irradiation or heat treated bacillus Calmette-Guerin Connaught. We measured the inhibition of cell proliferation and the production of cytokines in cell culture supernatants. Peripheral mononuclear blood cells were also infected and the production of different cytokines in cell culture supernatants was analyzed. Peripheral blood mononuclear cell and cell culture supernatants activated by mycobacteria were then cultured with T24 cells to analyze whether they showed cytotoxic activity. Compared to the other bacillus Calmette-Guerin treatments, g irradiated bacillus Calmette-Guerin showed activity similar to that of the live bacillus for inhibiting tumor growth and inducing cytokine production. Irradiated bacillus Calmette-Guerin showed metabolic activity and, thus, was considered killed but metabolically active. This is the treatment that most accurately preserved the mycobacterial structure. Killed but metabolically active bacillus Calmette-Guerin induced cytokine production by infected peripheral mononuclear blood cells. Mycobacteria activated peripheral blood mononuclear cell and cell supernatants showed cytotoxic activity against tumor cells, retaining the antitumor capacity of the live bacillus."
According to the news editors, the research concluded: "Our results suggest that killed but metabolically active bacillus Calmette-Guerin could be considered a safer immunotherapy alternative to treatment with the live bacillus."
For more information on this research see: Killed but Metabolically Active Mycobacterium bovis bacillus Calmette-Guerin Retains the Antitumor Ability of Live bacillus Calmette-Guerin. Journal of Urology, 2014;191(5):1422-1428. Journal of Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Journal of Urology - www.elsevier.com/wps/product/cws_home/706695)
The news correspondents report that additional information may be obtained from S. Secanella-Fandos, Autonomous University of Barcelona, E-08193 Barcelona, Spain. Additional authors for this research include E. Noguera-Ortega, F. Olivares, M. Luquin and E. Julian (see also Biotechnology).
Keywords for this news article include: Biotechnology, Spain, Europe, Barcelona, Immunotherapy, Actinobacteria, Immunomodulation, Mycobacteriaceae, Gram-Positive Rods, Mycobacterium bovis, Mycobacterium Infections, Actinomycetales Infections, Gram-Positive Asporogenous Rods, Gram-Positive Bacterial Infections
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC